anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A dentifrice (including ointment), a mouth wash, chewing-gum or a lozenge contain as an essential active ingredient a compound of formula &lt;FORM:0824680/VI/1&gt; where R is a hydroxymethyl or aminoethyl group and X is a hydrogen atom, or R is a formyl group and X is a hydrogen atom or a phosphonyl group or a salt or complex of such a compound. Compounds so included are pyridoxine, pyridoxamine, codecarboxylase, pyridoxamine phosphate, Vitamin B6-borate complex, and pyridoxal, i.e. 2-methyl-3-hydroxy-4 - formyl - 5 - hydroxymethyl pyridine and their salts such as the hydrochloride.  The amount included in the preparations may be from 0.05 to 5% by weight. Pantoyltaurine and bis - betapantoylaminoethyl disulphide may be added to the composition to interfere with L.acidophilus and pantothenic acid metabolism. Papain, to digest protein, may be added to chewing gum or, as in Example 8, to a toothpowder containing pyridoxine hydrochloride as active ingredient.  A dental ointment, Example 3, consists of pyridoxal hydrochloride 0.005 gms; white wax 0.054 gms; white petrolatum 0.941 gms.
A care service transaction method and system thereof are disclosed. The method comprises the following steps. First, a thermal camera and a control apparatus are disposed in a care place. User&#39;s health data is then received, and a care condition is determined based on the health data, and a cost is determined based on the care condition. The control apparatus is set to control the thermal camera based on the care condition, upon reception of paid information. Therefore, the user can buy suitable intelligent care service, such as care in various time period, area or care level, upon his/her demand.
PROBLEM TO BE SOLVED: To obtain the subject skin preparation for external use capable of imparting a barrier layer for irritant materials different in water solubility, oil solubility, etc., to the outermost surface of skin and effective in improving roughened skin by including plural polymers capable of mutually forming percolation structures when formed into a film. SOLUTION: This skin preparation for external use is obtained by including two or more kinds of polymers capable of mutually forming percolation structures when formed into a film (a modulated structure in spinodal decomposition in phase-separation behavior between incompatible different kinds of polymers), e.g. (A) a polymer having &lt;7.5×10-6 m3 (STP) m/m2.s.kPa water vapor transmission coefficient (e.g. pullulan) and (B) a polymer having &gt;=7.5×10-6 m3 (STP) m/m2.s.kPa water vapor transmission coefficient (e.g. polyethylene glycol). The formulation ratio of the ingredients is preferably (10/90) to (90/10) of the ingredients A and B expressed in terms of weight ratio and the total amount of the ingredients A and B is preferably 0.001-60 wt.% in the total composition.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide the use of a β-endorphin-mimetic agent in cosmetic and dermatology, and to provide a medicine for a new cosmetic treatment method.  &lt;P&gt;SOLUTION: At least one compound chosen from β-endorphin and the β-endorphin-mimetic agent is used on the keratinocytes of the skin. The β-endorphin-mimetic agent is chosen from aqueous, alcoholic and/or aqueous-alcoholic extracts of a plant of Theobroma cacao. The cosmetic composition to enhance the barrier function of the skin, enhance its resistance to stress and in particular to pollution is also provided. The compound is used in the method of cosmetic treatment for enhancing the barrier function and/or the moisturization of the skin and/or mucous membranes.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE:To obtain the subject compound useful as an anticancer agent by adding a trivalent iron ion source, etc., to anhydrovinblastine in the presence of oxygen, completing reaction, then adding a tridentate ligand to the iron ions in the reaction solution and carrying out ligand exchange. CONSTITUTION:A trivalent iron ion source (preferably hydrochloride, sulfate or nitrate), an oxalate ion source and a hydride source (e.g. sodium boron hydride) are added to anhydrovinblastine in the presence of oxygen and the resultant product is separated. In the process, a tridentate ligand (preferably trisodium citrate) is added to the iron ions in the reaction solution to carry out ligand exchange after completing the reaction. The pH is then preferably regulated to &gt;=6.5 and the formed product is subsequently extracted with an organic solvent (preferably 1,2-dichloroethane, etc.) immiscible with the aforementioned reaction solution. The resultant extract is then subjected to column chromatography to afford the objective compound.
PURPOSE:To maintain the activity of the antigen reacting specifically with a self antibody for a long period of time by treating the antigen which can react specifically with the self-antibody with an independent aq. soln. of 1 or &gt;=2 kinds among a saccharide, chelate agent, egg white albumin, gelatin and &#39;Ficoll(R)&#39; or a soln. mixture composed thereof and cow serum albumin in the stage of conjugating the antigen with an insoluble support. CONSTITUTION:The antigen is dissolved in a suitable solvent and is immersed together with the insoluble support in order to conjugate the antigen with the insoluble support. The isoluble support is pretreated with poly-L-lysine, methylated cow serum albumin, etc. The soln. of the antigen is removed after such immersion and the base is cleaned with physiological salt soln. by which the antigen-conjugated insoluble support is obtd. The insoluble support is then immersed into the independent aq. soln. of compd 1 or &gt;=2 kinds selected from the grop consisting of the saccharide, chelate agent, egg white albumin, gelatin and &#39;Ficoll(R)&#39; or the soln. mixture composed thereof and cow serum albumin and after the immersion, the aq. soln. is removed and the support is cleaned with the physiological salt soln, by which the stable solid phase reagent is obtd.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a hair follicle apoptosis inhibitor having prevention of fallen hair caused by hair follicle apoptosis and growth promotion effect of healthy hair thereby, and a hair cosmetic composition in which the hair follicle apoptosis inhibitor is formulated.  &lt;P&gt;SOLUTION: The hair follicle apoptosis inhibitor excellent in effects comprises both of the antioxidant and the antiinflammatory substance. The hair cosmetic composition is obtained by using the hair follicle apoptosis inhibitor. The antioxidant includes piroctone olamine, a plant extract selected from a specific group, carotenoid, ascorbic acid, coenzyme Q10, glutathione or the like. The antiinflammatory substance includes glycyrrhetic acid and/or its derivative, glycyrrhizic acid and/or its derivative, allantoin, a plant extract selected from a group other than that of the antioxidant.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To allow the inhibition of monocyte attractant activity by mutating a region of MCP-1.  &lt;P&gt;SOLUTION: Successful inhibition of the monocyte attractant activity has been found where the MCP-1 is modified in one or more of the followings: (a) the 28-tyrosine is substituted by aspartate, (b) the 24-arginine is substituted by phenylalanine, (c) the 3-aspartate is substituted by alanine, and/or (d) the 2-8 amino acid sequence is deleted. The claimed MCP-1 derivatives can be administered to a patient in need of inhibiting MCP-1 monocyte attractant activity. For example, the derivatives can be used to prevent restenosis, such as that which is common to patients undergoing coronary artery angioplasty. The invention further relates to compositions and methods of inhibiting monocyte attractant activity of MCP-1 employing the derivatives described.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The invention requests to protect an application of an RRY tripeptide in preparation of a drug for treating Alzheimer&#39;s disease and belongs to the field of medicines. The RRY tripeptide is definite in animal dosage and can be prepared into tablets, microspheres, powders, oral liquids and injections. The RRY tripeptide, when being used in treatment of the Alzheimer&#39;s disease, can be used individually and can be used in combination with other Alzheimer&#39;s disease drugs in different action mechanisms. When a drug composition composed of the RRY tripeptide, tetrandrine and triptolide is employed in treatment of the Alzheimer&#39;s disease, not only are toxic and side effects of the drug reduced, but also a synergistic treatment effect can be achieved. A pharmacologic experiment proves that the RRY tripeptide can effectively inhibit aggregation of A[beta]1-42 and prevent oligomerization of A[beta]1-42 monomer, and can significantly inhibit deposition of [beta] amyloid protein. The RRY tripeptide, when being used for preventing or treating the Alzheimer&#39;s disease, is definite in curative effect and is less in side effects so that the RRY tripeptide has a wide medical application prospect.
&lt;P&gt;PROBLEM TO BE SOLVED: To control the adhesive property of neutrophils.  &lt;P&gt;SOLUTION: As the first step of neutrophil infiltration into inflammation sites, neutrophils adhere to or interact with vascular endothelial cells. It is important to elucidate the system that controls the adhesive property acquired by the neutrophils against endothelial cells, for understanding and controlling the physical phenomena such as inflammation and other diseases involving neutrophils. Controlling the adhesive property of neutrophils is useful for developing pharmaceuticals, diagnostic agents, screening methods, diagnosis methods, etc. Galectin-8 has a strong neutrophil adhesion-inducing action which is reversible and inhibited by sugar analogs. Integrin αM and proMMP-9 have been identified as galectin-8-binding factors expressed in neutrophils. By inhibiting or adjusting the binding between these factors and galectin-8, the neutrophil adhesion-inducing action can be adjusted, enabling research and development of prophylactic and therapeutic pharmaceuticals, diagnostic agents, etc., for diseases involving neutrophils.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
Botulinum toxin has been shown to be useful for the treatment of pain when administered for cervical dystonia. Given efficacy for pain relief in regional dystonia, further expanded applications have included myofascial pain, muscle tension headaches, and other forms of headache syndromes. The application in headache practice has expanded to migraine as well as certain secondary headache syndromes. Although multiple case reports involving the use of botulinum toxin have shown promise in its utility for the treatment of primary pain syndromes, to date, controlled trials have failed to consistently and more definitively prove utility. Described herein is a method for selection of patients with headache syndromes more likely to respond to botulinum administration. The method involves identifying coincident diseases and signs within the patient&#39;s medical history, and selecting such patients for induction into clinical studies for pain or preferential primary treatment of pain using a botulinum based pharmaceutical.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a moisturizing plant extract which continues a moisturizing effect for a long time, and compositions of an external preparation, a cosmetic, a bath preparation and a detergent which contain the extract.  &lt;P&gt;SOLUTION: The moisturizing plant extract comprises an extract of a mixture of Rehmannia glutinosa Liboschitz var. purpurea Makino or Rehmannia glutinosa Liboschitz, Sophora flavescens Aiton, and Scutellaria baicalensis Georgi. The compositions of a cosmetic, a bath preparation, and a detergent comprise the extract. The extract has the same composition as the composition of a decoction of the above crude drugs at a specified ratio which is called as three-substance Scutellaria root decoction in Chinese medicine and is to be used for various skin diseases having warm sensation and itchiness by oral administration. The extract of the mixture of these crude drugs comprises a moisturizing plant component which continues a moisturizing effect for a long time, and its external use is effective for the prevention, alleviation or amelioration of drying of the skin, rough skin, chapping, cracks in the skin, dandruff, itchiness, and inflammatory diseases and, with the hair, is effective for drying, dry hair, split ends, broken hairs, gloss impartation and the like.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The invention discloses a traditional Chinese medicine mixture for treating the pediatric membranous nephropathy. The traditional Chinese medicine holds that the pediatric membranous nephropathy belongs to the &#39;edema&#39; range and relates to the lung, spleen and kidney three-viscera malfunction. Most of the pediatric membranous nephropathy is mainly characterized by insufficiency of both the spleen and the kidney, blood stasis obstructing the collaterals and internal stagnation of fluid-dampness. The operations of treating the root and strengthening the body resistance serve as the principal, and the operations of warming kidney and eliminating damp are assisted on the basis of invigorating spleen, supplementing qi and invigorating the circulation of blood. Therefore, the traditional Chinese medicine mixture for treating the pediatric membranous nephropathy is prepared from the following traditional Chinese medicines of plantain seed, semen coicis, rust-coloured crotalaria herb with root, herba lycopi, the root of bidentate achyranthes, rhizoma sparganii, astragalus mongholicus, boschniakia rossica, herba epimedii, rhizoma polygonati and rhizoma atractylodis, wherein the traditional Chinese medicines have the efficacy on tonifying Qi, lifting yang, removing blood stasis, and inducing diuresis to alleviate edema. The obtained traditional Chinese medicine mixture is taken by patients. According to the clinical test of our hospital, the total effective rate of the traditional Chinese medicine mixture is 93.3%, and a treatment group is obviously superior to a control group on the aspects of lowering cholesterol (CHOL) and urine protein and improving albumin (ALB) and clinic efficiency.
A process for delivering hair removal fluids to hair ducts. In a preferred embodiment the fluid is a vaccine for slowing or stopping hair growth and a process for applying the vaccine or other hair growth vaccines to the skin region having unwanted hair and a method of delivering the vaccine to skin regions of unwanted hair. The preferred vaccine consists of an antigen cocktail of weakened or essentially dead elements of hair follicles for stimulating antibody responses. The preferred vaccine is prepared from patient&#39;s own hair papilla or bulge area stem cells. In other embodiments vaccines are made from extracts of papilla cells cultivated in a laboratory. The vaccines produce antibodies and these antibodies attack and destroy hair papilla and block bulge area cells that would otherwise produce or stimulate a growth of new papilla cells.
PCT No. PCT/HU95/00011 Sec. 371 Date Apr. 16, 1996 Sec. 102(e) Date Apr. 16, 1996 PCT Filed Apr. 25, 1995 PCT Pub. No. WO95/29172 PCT Pub. Date Nov. 2, 1995New inclusion complexes which are stable in their so-lid state formed of SIN-1A and cyclodextrins or cyclodextrin derivatives and optionally also containing ions as catalyst or stabilizer. The complexes release nitric oxide at room temperature upon dissolving in water or aqueous systems. The ions are preferably carboxylic acid anions such as acetate, formiate, propionate, ascorbinate, tartarate and/or lactate and/or inorganic acid anions such as phosphate, phosphite, borate, carbonate, hydrocarbonate, sulfate, sulfite and/or cations such as alkali and/or ammonium. Pharmaceutical compositions as well as kits containing the complexes. The kits are to be used as NO-liberating standards to release NO in a predictable amount and rate on dissolving in aqueous media. Processes for the preparation of the complexes by subjecting at a suitable pH SIN-1 to the catalytic action of ions to shift the equilibrium towards formation of SIN-1A in the presence of cyclodextrins or cyclodextrin derivatives capable to form inclusion complexes, whereby the SIN-1A formed is immediately complexed and stabilized and isolating in the solid state the obtained new complexes optionally containing ions. A preferred process includes reacting SIN-1 and a cyclodextrin or cyclodextrin derivative in the solid state in the presence of a salt as a catalyst by thoroughly admixing or milling the components together or by freeze drying an aqueous, oxygen-free solution containing the components, followed preferably by &#34;second drying&#34; in vacuo.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a fat absorption inhibitor and a drug, a health food or a pet food which inhibits fat absorption and has the effectiveness of preventing or improving life style related diseases such obesity, diabetes, arteriosclerosis, and hyperlipemia.  &lt;P&gt;SOLUTION: This drug, health food or pet food has a component present in Anthurium andraeanum cv. Compactum. This component may be incorporated using its entire plant or leaves thereof as such or a dried product obtained by drying them or a pulverized powder after drying. Further, as the above component, an extract obtained by extracting them with water or an organic solvent such as an alcohol may be used.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new treating method for treating regressive arthritis.  &lt;P&gt;SOLUTION: A cell-mediated gene therapy utilizing one member belonging to a transforming growth factor-β (TGF-β) superfamily is provided for treating orthopedic diseases. After transfection of TGF-β cDNA expression vectors into fibroblasts (NIH 3T3-TGF-β1), the cells were injected into an achilles tendon and a knee joint of a rabbit with artificially-made cartilage defects. Intratendinous injections were performed to determine the optimal concentration for in vivo expression. Partially defected cartilage model was made to confirm stimulation of regressive arthritis of the knee joint. The partial cartilage defect treated with the cell-mediated gene therapy procedure was covered with newly formed hyaline cartilage, which indicates that the cells are survived and stimulated of matrix formation in this region. Completely denuded cartilage areas were covered with fibrous collagen.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE: To enjoy favorable refreshingness in summer season and have skin firmness effect owing to low temperatures, by using a makeup cosmetic prepared by formulating specific powder, lubricant and water in specified proportions after its chilling in e.g. a refrigerator. CONSTITUTION: A makeup cosmetic composed of 93-10wt.% of water-repelling- treated powder, 2-40wt.% of a lubricant and 5-50wt.% of water is chilled to a temperature &gt;=0 deg.C lower than room temperature. The powder is e.g. titanium dioxide, zinc oxide. The water-repelling treatment is carried out by using e.g. a fluorine compound. The lubricant is e.g. stearyl alcohol, glycerol, isostearic acid, vaseline.
The invention comprises compounds of the general formula: &lt;FORM:0856505/IV(b)/1&gt; wherein R1 and R2, which may be the same or different, are hydrogen atoms, C1-4 alkyl radicals or acyl radicals, or, together with the adjacent nitrogen atom, they may form a heterocyclic ring which may contain an oxygen or sulphur atom, and R3 is a chlorine or bromine atom or a mercapto or alkyl mercapto radical; and the preparation thereof by the following processes: (a) where NR1R2 is an amino or heterocyclic group and R3 is a halogen atom, by reacting a 6, 7-dihalo-5, 8-quinolinequinone with HNR1R2; (b) where NR1R2 is an acyl amino group and R3 is a halogen atom, by acylating the corresponding amino compound; (c) where R3 is a mercapto group, by treating the corresponding halogeno compound with hydrogen sulphide or a salt thereof; and (d) where R3 is alkyl mercapto, by alkylating the corresponding mercapto compound or by reacting the corresponding halogeno compound with an alkali-metal mercaptile; and pharmaceutical compositions containing the products (see Group VI).  The products are active against Actinomycetes.  6, 7- Dichloro-5, 8-quinolinequinone is prepared by oxidative chlorination of 5-amino-8-hydroxy-quinoline.  6, 7- Dibromo-5, 8-quinolinequinone is prepared by treating 5-amino-8-hydroxy-quinoline with sodium bromate and hydrobromic acid.ALSO:Pharmaceutical compositions comprise compounds of the general formula:  &lt;FORM:0856505/VI/1&gt; wherein R1 and R2, which may be the same or different, are hydrogen atoms, C1-4 alkyl radicals or acyl radicals, or, together with the adjacent nitrogen atom, they may form a heterocyclic ring which may contain an oxygen or a sulphur atom, and R3 is a chlorine or bromine atom or a mercapto or alkyl mercapto radical, in admixture with 2-(p-aminobenzenesulphonamide) - pyrimidine or 2 - (p-aminobenzenesulphonamide) - 4 - methyl - pyrimidine combined with the 4-aminobenzenesulphothiocarbamide salt of 4-aminoethylbenzenesulphonamide and preferably an inert carrier, and if desired an analgesic such as aspirin.  The compositions may be in conventional pharmaceutical form e.g. a capsule, emulsion or solution.
PROBLEM TO BE SOLVED: To obtain the subject stable aqueous solution preparation by admixing β-lactoglobulin (β-LG) and human calcuitonin (h-CT). SOLUTION: This preparation is obtained by formulating β-LG one of protein components in milk to an aqueous solution of h-CT. In the production of this preparation, β-LG is dissolved in a suitable aqueous solvent as distilled water or tap water, the pH of the solution is adjusted to &lt;=4, then h-CT is dissolved therein. The concentration of h-CT is suitably 0.5-10 mg/ml, β-LG is 1-40 mg/ml, suitably. This preparation may contain a mucous absorption promoter, stimulation alleviator, isotonizing agent, thickener, preservative and other additives. Since β-LG is formulated, the preparation is stable since its coagulation of h-CT is delayed.
The application discloses apparatuses, systems and methods for selecting a base data entry for distribution with a content provider&#39;s requested content. More specifically, the disclosed system may be configured to receive and process a distribution advertisement request from a content provider or an affiliate. The system processes the advertisement request to extract content provider distribution parameters and/or web user data characteristics, if they exist. This data may be processed to create an initial a pool of potential base data entries, one (or more) of which will be distributed to a content provider. In an implementation, the system further processes the initial pool based on sponsor distribution parameters associated with the various base data entries that comprise the pool. Based on this analysis, the system selects one or more of the potential base data entries based on a variety of ad distribution considerations.